Tel:
Fax:
Email:
Creative Biolabs
Product

NeuroMab™ Anti-CD20 BBB Shuttle Antibody (NRZP-1022-ZP3884)

[CAT#: NRZP-1022-ZP3884]

Host Species:
Humanized
Species Reactivity:
Human
Applications:
ADCC; CDC; FC; In Vitro

Datasheet MSDS Request COA

Certificate of Analysis Lookup
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number

Inquiry

SPECIFIC INQUIRY

inquiry
Size:
Conjugation:
Endotoxin:
Purity:
Engineering:
Product Overview

Description

Brain uptake of therapeutic antibodies is severely limited by their size. To achieve enhanced BBB crossing, Creative Biolabs developed a BBB shuttle antibody platform by utilizing the endogenous macromolecule transportation pathway, known as receptor-mediated transcytosis (RMT). The engineered antibody-based carrier is believed to significantly to increase the macromolecule brain entry to combat CNS diseases.
Notes: The BBB antibody is made-to order and available in a customized format. Please don't hesitate contact us for more details.

Species Reactivity

Human

Clonality

Monoclonal

Host Species

Humanized

Applications

ADCC; CDC; FC; In Vitro
Product Properties

Storage

Store at -20°C. Do not aliquot the antibody.

Research Use Only

For research use only
Target

Target

CD20

Official Name

MS4A1

Full Name

B-lymphocyte antigen CD20

Alternative Names

MS4A1; B1; Bp35; CD20; CVID5; LEU-16; MS4A2; S7; membrane spanning 4-domains A1; FMC7
Product Pictures
CDC

Figure 1 CDC of wild-type and E345R mutants of CD20 antibody HuMAb 7D8 in competition experiments with Fc-binding peptides.

CDC

Figure 2 CDC mediated by 7D8 variants on CD20-positive Raji cells.

CDC

Figure 3 CDC mediated by 7D8 mutants (7D8-WT, K439E, S440K, K439E/S440K double mutant, K439E+S440K mixed) on CD20-positive Daudi cells.

FuncS

Figure 4 Plasma concentrations of wild-type IgG1-7D8 and -E354R, -S440K and K322A variants after intravenous injection in SCID mice.

CDC

Figure 5 CDC on CD20 and CD38 positive Wien133 cells.

FuncS

Figure 6A Evaluation of the in vivo efficacy of IgGl-7D8-E345R in a subcutaneous xenograft model using Raji-luc #2D1 cells.

FuncS

Figure 6B Evaluation of the in vivo efficacy of IgGl-7D8-E345R in a subcutaneous xenograft model using Raji-luc #2D1 cells.

CDC

Figure 7 CDC Kinetics. Introduction of the E345R mutation in the bispecific antibody CD38×EGFR, which monovalently binds EGFR-negative Raji cells, resulted in more rapid and massive CDC-mediated lysis of target cells.

CDC

Figure 8A CDC of CD20-positive, CD38-negative Wienl33 cells or Raji cells by CD20/CD38 bispecific antibodies with and without the E345R mutation.

CDC

Figure 8B CDC on CD20 positive, CD38 negative Wienl33 cells or Raji cells by CD20/CD38 bispecific antibody with and without E345R mutation.

CDC

Figure 9 CDC of CD38-positive, EGFR-negative Wien133 cells by CD38/EGFR bispecific antibody with E345R mutation.

ELISA

Figure 12A Binding of wild-type IgG1-7D8 and mutant IgG1-7D8-E345R to human FcRn as determined by ELISA at pH 6.

ELISA

Figure 12B Binding of wild-type IgG1-7D8 and mutant IgG1-7D8-E345R to cynomolgus FcRn as determined by ELISA at pH 6.

ELISA

Figure 12C Binding of wild-type IgG1-7D8 and mutant IgG1-7D8-E345R to mouse FcRn as determined by ELISA at pH 6.

Publications

Publications (0)

gift-card

Related Products
For Research Use Only. Not For Clinical Use.
Send Inquiry Send Inquiry
Inquiry Basket
compare

Send inquiry